An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1

- Must have received and progressed on or failed one standard/approved treatment for
cancer type, if available

- At least 4 weeks since any previous treatment for cancer

- Subject must consent to pretreatment and on treatment tumor biopsies

- At least one lesion with measurable disease at baseline

- Adequate organ and marrow function

Exclusion Criteria:

- Patients with primary brain tumors or primary tumors with central nervous system
metastases as only location of disease. Controlled brain metastases are permitted

- Prior organ transplant

- Participants with second/other active cancers requiring current treatment

- Uncontrolled/significant heart disease

- History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or
Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency
Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)

- Active/uncontrolled autoimmune disease

- Active infection

Other protocol defined inclusion/exclusion criteria could apply